published meta-analysis   sensitivity analysis   studies

sotrovimab (Xevudy; VIR-7831) in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOMET-ICE, 2021 0.25 [0.01; 5.55] 0.25[0.01; 5.55]COMET-ICE, 202110%1,057NAnot evaluable deathsdetailed resultsCOMET-ICE, 2021 0.25 [0.01; 5.55] 0.25[0.01; 5.55]COMET-ICE, 202110%1,057NAnot evaluable hospitalization or deathdetailed resultsCOMET-ICE, 2021 0.21 [0.09; 0.49] 0.21[0.09; 0.49]COMET-ICE, 202110%1,057NAnot evaluable clinical deteriorationdetailed resultsCOMET-ICE, 2021 0.24 [0.10; 0.56] 0.24[0.10; 0.56]COMET-ICE, 202110%1,057NAnot evaluable hospitalizationdetailed resultsCOMET-ICE, 2021 0.20 [0.08; 0.48] 0.20[0.08; 0.48]COMET-ICE, 202110%1,057NAnot evaluable adverse eventsdetailed resultsCOMET-ICE, 2021 0.91 [0.68; 1.22] 0.91[0.68; 1.22]COMET-ICE, 202110%1,049NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-03-28 14:07 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 880 - roots T: 290